Symbiotec Pharmalab IPO | Top Management On Growth Plans, Business Outlook & IPO Strategy

Symbiotec Pharmalab is making its market debut with its IPO, and investors are closely tracking the issue, growth outlook and business strategy. In this special conversation, we speak to the top management of Symbiotec Pharmalab — Chairman & MD Anil Satwani and CFO Raghavender Ramachandran — to understand the company’s plans and priorities. We discuss the IPO strategy, business outlook, CDMO operations, manufacturing capabilities and expansion plans across chemistry, biotech and injectables. The management also shares its view on growth opportunities, new facilities, capacity expansion and the company’s global ambitions. Tune in for key insights directly from Symbiotec Pharmalab’s top management.